Read by QxMD icon Read

Multiple Sclerosis Journal—Experimental, Translational and Clinical

Naila Makhani, Christine Lebrun, Aksel Siva, Sona Narula, Evangeline Wassmer, David Brassat, J Nicholas Brenton, Philippe Cabre, Clarisse Carra Dallière, Jérôme de Seze, Francoise Durand Dubief, Matilde Inglese, Megan Langille, Guillaume Mathey, Rinze F Neuteboom, Jean Pelletier, Daniela Pohl, Daniel S Reich, Juan Ignacio Rojas, Veronika Shabanova, Eugene D Shapiro, Robert T Stone, Silvia Tenembaum, Mar Tintoré, Ugur Uygunoglu, Wendy Vargas, Sunita Venkateswaren, Patrick Vermersch, Orhun Kantarci, Darin T Okuda, Daniel Pelletier
Background: Steps towards the development of diagnostic criteria are needed for children with the radiologically isolated syndrome to identify children at risk of clinical demyelination. Objectives: To evaluate the 2005 and 2016 MAGNIMS magnetic resonance imaging criteria for dissemination in space for multiple sclerosis, both alone and with oligoclonal bands in cerebrospinal fluid added, as predictors of a first clinical event consistent with central nervous system demyelination in children with radiologically isolated syndrome...
January 2019: Multiple Sclerosis Journal—Experimental, Translational and Clinical
R H Gross, S H Sillau, A E Miller, C Farrell, S C Krieger
Background: The Multiple Sclerosis Severity Score (MSSS), combining the Expanded Disability Status Scale (EDSS) and disease duration, attempts to stratify multiple sclerosis (MS) patients based on their rate of progression. Its prognostic ability in the individual patient remains unproven. Objectives: To assess the stability of MSSS within individual persons with MS in a longitudinal cohort, to evaluate whether certain factors influence MSSS variability, and to explore the ability of MSSS to predict future ambulatory function...
January 2019: Multiple Sclerosis Journal—Experimental, Translational and Clinical
Gustavo Saposnik, Jorge Maurino, Angel P Sempere, Maria A Terzaghi, Maria Pia Amato, Xavier Montalban
Conferences traditionally play an important role in the ongoing medical education of healthcare professionals. We assessed the influence of attending the ECTRIMS congress on therapeutic decision-making in multiple sclerosis (MS) care. A non-interventional, cross-sectional study involving 96 neurologists was conducted. Treatment escalation when therapeutic goals were unmet and management errors related to tolerability and safety scenarios of MS therapies were tested using different case-scenarios. Attendance at ECTRIMS was associated with an increase likelihood of treatment escalation in the presence of clinical progression (cognitive decline) and radiological activity (OR 2...
January 2019: Multiple Sclerosis Journal—Experimental, Translational and Clinical
Dominique Kinnett-Hopkins, Robert Motl
Background: The promotion of exercise among black individuals with multiple sclerosis (MS) is important for managing the functional and symptomatic manifestations of MS. Objective: The objective of this study was to elicit exercise program preferences among black individuals with MS. Methods: Participants completed a survey delivered through Qualtrics. The survey measured exercise program component preferences, the importance of racial considerations, and barriers and facilitators to exercise participation...
January 2019: Multiple Sclerosis Journal—Experimental, Translational and Clinical
D D Wilkie, A Solari, R Nicholas
Introduction: Initiating disease-modifying treatments (DMTs) in multiple sclerosis (MS) is a major decision for people with (pw)MS but little is known about how the decision is perceived by the individual. Objectives: The aim of the study was to determine if decisional conflict (DC) and decisional regret reflect different stages of the decision-making process when initiating DMTs. Methods: This was a cross-sectional study of three cohorts of pwMS ( n  = 254), a 'MS conference attendees', 'on treatment' and an 'offered treatment' cohort...
January 2019: Multiple Sclerosis Journal—Experimental, Translational and Clinical
Afsaneh Shirani, Anne H Cross, Robert T Naismith
A relationship between handedness and clinicodemographic profiles of people with multiple sclerosis was sought using data from the Multiple Sclerosis Partners Advancing Technology Health Solutions network of 10 multiple sclerosis centers in the USA and Europe. Handedness data were available for 8888 multiple sclerosis patients, of which 917 (10.3%) were left-handed. Clinicodemographic profiles of right versus left-handed multiple sclerosis patients were similar except for a slightly increased proportion of men who were left-handed, and slightly reduced performance on the manual dexterity test using the non-dominant hand in left-handed patients...
January 2019: Multiple Sclerosis Journal—Experimental, Translational and Clinical
Mattia Rosso, Dorlan J Kimbrough, Cindy T Gonzalez, Bonnie I Glanz, Brian C Healy, Maria Assunta Rocca, Massimo Filippi, Howard Weiner, Tanuja Chitnis
Background: Optical coherence tomography (OCT) provides quantitative measures of retinal layer thickness. Cigarette smoking is a risk factor for multiple sclerosis (MS) onset and disease severity: its effects on OCT metrics have not been assessed. Objective: The objective of this study was to assess the effect of smoking history on retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform (GCIP) of MS patients by OCT. Methods: 112 MS patients were recruited from the Brigham and Women's Hospital...
January 2019: Multiple Sclerosis Journal—Experimental, Translational and Clinical
Sarah L Minden, R Philip Kinkel, Helene T Machado, Jonathan S Levin, Meredith B Rosenthal, Lisa I Iezzoni
Background: Disease-modifying therapies benefit individuals with relapsing forms of multiple sclerosis, but their utility remains unclear for those without relapses. Objective: To determine disease-modifying therapy use and costs in 2009, compare use in 2009 and 2000, and examine compliance with evidence-based guidelines. Methods: We determined the extent and characteristics of disease-modifying therapy use by participants in the Sonya Slifka Longitudinal Multiple Sclerosis Study (Slifka) in 2000 ( n =2156) and 2009 ( n =2361) and estimated out-of-pocket and total (payer) costs for 2009...
January 2019: Multiple Sclerosis Journal—Experimental, Translational and Clinical
(no author information available yet)
No abstract text is available yet for this article.
January 2019: Multiple Sclerosis Journal—Experimental, Translational and Clinical
Isaiah Kletenik, Enrique Alvarez, Justin M Honce, Brooke Valdez, Timothy L Vollmer, Luis D Medina
Objective: Brain atrophy has been correlated with objective cognitive dysfunction in multiple sclerosis but few studies have explored self-reported subjective cognitive concerns and their relationship to brain volume changes. This study explores the relationship between subjective cognitive concerns in multiple sclerosis and reduced brain volume in regions of interest implicated in cognitive dysfunction. Methods: A total of 158 patients with multiple sclerosis completed the Quality of Life in Neurologic Disorders Measures (Neuro-QoL) short forms to assess subjective cognitive concerns and underwent brain magnetic resonance imaging...
January 2019: Multiple Sclerosis Journal—Experimental, Translational and Clinical
Johan Linden, Gabriel Granåsen, Jonatan Salzer, Anders Svenningsson, Peter Sundström
Background: Most multiple sclerosis patients on disease-modifying treatment at Umeå University Hospital are treated with rituximab and the prevalence of vitamin D supplementation has increased over time. Follow-up studies of these off-label treatments are needed. Objective: To study inflammatory activity and adverse effects in rituximab-treated multiple sclerosis patients, and associations with 25-hydroxy-vitamin D levels. Methods: Retrospectively collected data on repeated estimates of relapses, disability, side effects, magnetic resonance imaging, laboratory measures including 25-hydroxy-vitamin D levels and self-perceived health...
January 2019: Multiple Sclerosis Journal—Experimental, Translational and Clinical
Nathalie Ackermans, Carolyn Taylor, Roger Tam, Robert Carruthers, Shannon Kolind, Heejun Kang, Mark S Freedman, David Kb Li, Anthony L Traboulsee
Objective: The objective of this paper is to evaluate potential dose-dependent adverse effects of gadolinium-based contrast agents (GBCAs) on MS progression. Methods: Outcomes from a cohort of 612 secondary progressive MS (SPMS) patients, enrolled in a two-year, placebo-controlled (negative) trial assessing the efficacy of MBP8298, were acquired. Patients received one to four (infrequent cohort; IFR) or 5-11 (frequent cohort; FR) GBCA injections between week 4 and week 104...
January 2019: Multiple Sclerosis Journal—Experimental, Translational and Clinical
Stanley L Cohan, Keith Edwards, Lindsay Lucas, Tiffany Gervasi-Follmar, Judy O'Connor, Jessica Siuta, Vineetha Kamath, Lore Garten, Chiayi Chen, James Thomas, Kyle Smoot, Kiren Kresa-Reahl, Kateri J Spinelli
Background: Natalizumab is an effective treatment for relapsing multiple sclerosis. Return of disease activity upon natalizumab discontinuance creates the need for follow-up therapeutic strategies. Objective: To assess the efficacy of teriflunomide following natalizumab discontinuance in relapsing multiple sclerosis patients. Methods: Clinically stable relapsing multiple sclerosis patients completing 12 or more consecutive months of natalizumab, testing positive for anti-John Cunningham virus antibody, started teriflunomide 14 mg/day, 28 ± 7 days after their final natalizumab infusion...
January 2019: Multiple Sclerosis Journal—Experimental, Translational and Clinical
Lisa Eunyoung Lee, Jillian K Chan, Emilie Nevill, Adam Soares, Irene M Vavasour, Erin L MacMillan, Hideki Garren, David Clayton, B Mark Keegan, Roger Tam, Anthony L Traboulsee, Shannon H Kolind, Robert L Carruthers
Background: Progressive solitary sclerosis is a unifocal demyelinating disease recently proposed as a possible multiple sclerosis variant. Objective: To compare myelin content and brain metabolite ratio qualitatively in the normal-appearing white matter of progressive solitary sclerosis cases compared to multiple sclerosis and healthy control participants. Methods: Case report. Results: Progressive solitary sclerosis cases showed abnormal myelin in normal-appearing white matter tracts and global normal-appearing white matter as well as lower N-acetyl-aspartate to total creatine ratio compared to multiple sclerosis and healthy control groups...
January 2019: Multiple Sclerosis Journal—Experimental, Translational and Clinical
Robert T Naismith, Barry Hendin, Sibyl Wray, DeRen Huang, Fiorenza Gaudenzi, Qunming Dong, Bjørn Sperling, Monica Mann, Brian Werneburg
Background: Flu-like symptoms are common adverse events associated with interferon beta relapsing multiple sclerosis therapies. Objectives: To evaluate the incidence and severity of flu-like symptoms after transitioning from non-pegylated interferons to peginterferon beta-1a and assess flu-like symptom mitigation using naproxen. Methods: ALLOW was a phase 3b open-label study in relapsing multiple sclerosis patients. Patients had received non-pegylated interferon for 4 or more months immediately before beginning a 4-week screening period...
January 2019: Multiple Sclerosis Journal—Experimental, Translational and Clinical
Andrius Kavaliunas, Petter Tinghög, Emilie Friberg, Tomas Olsson, Kristina Alexanderson, Jan Hillert, Virginija Danylaite Karrenbauer
Background: In multiple sclerosis various aspects of cognitive function can be detrimentally affected. More than that, patients´ employment and social functioning is likely to be impacted. Objective: To determine whether work disability among multiple sclerosis patients could be predicted by the symbol digit modalities test. Methods: A register-based cohort study was conducted. Individual data on work disability, operationalised as annual net days of sickness absence and/or disability pension were retrieved at baseline, when the symbol digit modalities test was performed, after one-year and 3-year follow-up for 903 multiple sclerosis patients...
January 2019: Multiple Sclerosis Journal—Experimental, Translational and Clinical
Jeffrey A Cohen, Amit Bar-Or, Bruce A C Cree, Yang Mao-Draayer, May H Han, Barry Singer, Ann Jannu, Scott Kolodny, Xiangyi Meng, Ryan C Winger
Background: Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of patients with relapsing forms of multiple sclerosis (RMS). Fingolimod sequesters lymphocytes within lymphoid tissue thereby reducing the counts of circulating lymphocytes. However, fingolimod's effects on the innate and adaptive components of the immune system are incompletely understood. Objective: The FLUENT study will investigate temporal changes in circulating immune cell subsets in patients with RMS treated with fingolimod...
January 2019: Multiple Sclerosis Journal—Experimental, Translational and Clinical
Madhurima Chatterjee, Marleen Ja Koel-Simmelink, Inge Mw Verberk, Joep Killestein, Hugo Vrenken, Christian Enzinger, Stefan Ropele, Franz Fazekas, Michael Khalil, Charlotte E Teunissen
Background: Contactin-1 and contactin-2 are important for the maintenance of axonal integrity. Objective: To investigate the cerebrospinal fluid levels of contactin-1 and contactin-2 in multiple sclerosis patients and controls, and their potential use as prognostic markers for neurodegeneration. Methods: Cerebrospinal fluid contactin-1 and contactin-2 were measured in relapsing-remitting multiple sclerosis ( n =  41), secondary progressive multiple sclerosis ( n =  26) and primary progressive multiple sclerosis patients ( n =  13) and controls ( n =  18), and in a second cohort with clinically isolated syndrome patients ( n =  88, median clinical follow-up period of 2...
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
Patrick Aouad, Con Yiannikas, Suran L Fernando, John Parratt
Alemtuzumab is a high-efficacy disease-modifying therapy for the treatment of relapsing forms of multiple sclerosis and is associated with secondary autoimmune adverse events. We report a novel case of secondary autoimmune myositis that occurred seven months after the initial treatment cycle and achieved full recovery with oral corticosteroids. This particular form of myositis appears to be unique, and is likely to be a distinct entity from the other four types of immune-mediated myositis.
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
James D Bowen, Chris M Kozma, Megan M Grosso, Amy L Phillips
Background: Administrative-claims data enable comparative effectiveness assessment using large numbers of patients treated in real-world settings. Objective: To evaluate real-world relapses, healthcare costs and resource use in patients with MS newly initiating subcutaneous interferon beta-1a (sc IFNβ-1a) v. oral disease-modifying drugs (DMDs: dimethyl fumarate, fingolimod, teriflunomide). Methods: Patients from an administrative claims database (1 Jan 2012-31 Dec 2015) were selected if they: were 18-63 years old; had an MS diagnosis; had newly initiated sc IFNβ-1a, dimethyl fumarate, fingolimod, or teriflunomide (first claim = index); had no evidence of DMD 12-months pre-index; and had 12-month eligibility pre- and post-index...
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"